Mesahenz 1200 Tablet PR
In Stock • people bought this
Delivery : 2-4 days PAN India
Seller : Davadost pharma private limited
People who purchased Mesahenz 1200 Tablet PR also bought
Discover the Benefits of ABHA Card registration
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHAIntroduction to Mesahenz 1200 Tablet PR
Mesahenz 1200 Tablet PR is generally recommended to handle different inflammatory bowel conditions (IBD), such as ulcerative colitis and Crohn's disease, as an effective method to manage symptoms and stimulate or maintain remission.
Mesalazine is a part of the drug category referred to as amino salicylates, which are anti inflammatory agents strategically crafted to aim for the intestines' lining.
Usuallly, Mesalazine tablets are ingested orally with or minus meals, as per the instructions of your healthcare professional. Make sure to attend the follow up visits as planned to keep a check on your condition and reaction to the therapy.
Individuals who are prescribed this medication need to stick to their medical practitioner's advice on dosage and the period of treatment.
It is very significant to immediately communicate any lasting symptoms or negative impacts.
How Mesahenz 1200 Tablet PR works
Mesahenz 1200 Tablet PR is a pharmaceutical product designed to counteract inflammatory bowel disease (IBD), a condition causing inflammation and ulcers in the colon and rectum. Mesaflux 1.2 SR Tablet operates by reducing the inflammation within the intestines by specifically targeting the disease in that region. Minimizing inflammation promotes the recuperation of the inner lining and aids in the relief of symptoms like abdominal discomfort, diarrhea, and rectal bleeding.
How To Use Mesahenz 1200 Tablet PR
- Abide by your physician's directives.
- Consume with meals to magnify its potency.
- Pursue the suggested quantity and period provided by your physician for superior outcomes.
- Ingest without modifying its shape to guarantee correct treatment.
Special Precautions for Mesahenz 1200 Tablet PR
- Inform your healthcare provider of any allergies or kidney issues.
- Monitor for signs of allergic reactions such as rash or difficulty breathing.
- Stay hydrated; drink plenty of fluids.
- Regularly check kidney function.
- Report any unusual bleeding or bruising promptly.
Benefits Of Mesahenz 1200 Tablet PR
- Suppressing inflammation in the gastrointestinal tract.
- Effectively manages and prevents ulcerative colitis relapses, ensuring sustained relief from symptoms over the long term.
- Promotes intestinal lining integrity for better digestive health.
Side Effects Of Mesahenz 1200 Tablet PR
- Nausea
- Abdominal pain
- Headache
- Stomach pain
- Diarrhea
- Flatulence
- Vomiting
What If I Missed A Dose Of Mesahenz 1200 Tablet PR
Disease Explanation
No disease explanation.
Safety Advice for Mesahenz 1200 Tablet PR
- High risk
- Moderate risk
- Safe
Consumption of alcohol could potentially exacerbate the symptoms of inflammatory bowel disease and may hinder the efficacy of medication.
Generally, it is deemed safe in pregnancy as it doesn't significantly absorb into the system. Nevertheless, it's imperative to consult with a healthcare professional about its usage during this period.
As a rule, it's safe during breastfeeding as it's not significantly absorbed into the system. Still, it's vital to consult with a healthcare professional when it's used during such periods.
In exceptional instances, it could impact kidney function. Hence, it's recommended to supervise kidney function whilst undergoing treatment.
In exceptional instances, it could lead to liver complications. Consequently, it's recommended to monitor liver function while on treatment.
FAQ's on Mesahenz 1200 Tablet PR
When is the best time to take Mesahenz?
How should I use Mesahenz?
Does Mesahenz cause joint pain?
My symptoms have improved can I stop taking Mesahenz?
I am suffering from ulcerative colitis (UC) and piles can I use Mesahenz?
Can I drink alcohol while taking Mesahenz?
Written By
Altaf Jawed
Content Updated on
Monday, 24 November, 2025
